CLINICAL TRIALS PROFILE FOR PULMICORT FLEXHALER
✉ Email this page to a colleague
All Clinical Trials for PULMICORT FLEXHALER
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00702325 ↗ | Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans | Completed | AstraZeneca | Phase 4 | 2008-06-01 | To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African American(self-reported) subjects with inhaled corticosteroid (ICS) dependent asthma. |
NCT01218399 ↗ | Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations | Completed | AstraZeneca | N/A | 2009-09-01 | This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone. |
NCT01218399 ↗ | Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations | Completed | Stanford University | N/A | 2009-09-01 | This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone. |
NCT01219738 ↗ | Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide | Completed | AstraZeneca | N/A | 2008-07-01 | Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists). |
NCT01219738 ↗ | Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide | Completed | University of Miami | N/A | 2008-07-01 | Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PULMICORT FLEXHALER
Condition Name
Clinical Trial Locations for PULMICORT FLEXHALER
Trials by Country
Clinical Trial Progress for PULMICORT FLEXHALER
Clinical Trial Phase
Clinical Trial Sponsors for PULMICORT FLEXHALER
Sponsor Name